Efficacy and Safety of Obinutuzumab in Relapsed or Refractory Hairy Cell Leukemia (R/R HCL): An Italian Multicenter Phase-2 Academic Trial (HCL-PG04)

被引：0
|
作者：
Tiacci, Enrico [1 ,2 ]
De Carolis, Luca [1 ,2 ]
Capponi, Monia [1 ,2 ]
Falcinelli, Flavio [1 ,2 ]
Zaja, Francesco [3 ,4 ]
Pulsoni, Alessandro [5 ]
Simonetti, Edoardo [1 ,2 ]
Montechiarello, Elisa [6 ]
Romano, Alessandra [7 ]
Olivieri, Jacopo [8 ]
Mancini, Alessandro [1 ,2 ]
D'Elia, Gianna Maria [9 ,10 ]
Foa, Robin [9 ,10 ]
Frezzato, Maurizio [11 ]
Falini, Brunangelo [2 ]
机构：
[1] Univ & Hosp Perugia, Inst Hematol, Perugia, Italy
[2] Univ & Hosp Perugia, Ctr Hematooncol Res, Perugia, Italy
[3] Univ Trieste, DSM, Trieste, Italy
[4] Azienda Sanit Univ Giuliano Isontina, UCO Ematologia, Trieste, Italy
[5] Univ Sapienza, SM Goretti Hosp, Hematol, Latina, Italy
[6] Hosp Reggio Calabria, Hematol, Reggio Di Calabria, Italy
[7] Univ & Hosp Catania, Hematol, Catania, Italy
[8] Azienda Sanit Univ Integrata Udine, Ctr Trapianti & Terapie Cellulari Carlo Melzi, Clin Ematol, Udine, Italy
[9] Univ Sapienza, Hematol, Rome, Italy
[10] Hosp Umberto I, Rome, Italy
[11] Hosp Vicenza, Hematol, Vicenza, Italy
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-180035
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] THE BRAF INHIBITOR VEMURAFENIB IS SAFE AND HIGHLY EFFECTIVE IN REFRACTORY AND RELAPSED HAIRY CELL LEUKEMIA: RESULTS OF THE HCL-PG01 PHASE-2 ITALIAN CLINICAL TRIAL
    Tiacci, E.
    De Carolis, L.
    Broccoli, A.
    Pulsoni, A.
    Mazzucco, M.
    Cimminiello, M.
    Ambrosetti, A.
    Rossi, D.
    Motta, G.
    Varettoni, M.
    Fraticelli, V.
    Carella, A. M.
    Anastasia, A.
    Leoni, P.
    Rambaldi, A.
    Falzetti, F.
    Ascani, S.
    Capponi, M.
    Martelli, M. P.
    Pileri, S. A.
    Foa, R.
    Zinzani, P. L.
    Falini, B.
    HAEMATOLOGICA, 2015, 100 : 1 - 2
  • [2] Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial
    Tiacci, Enrico
    De Carolis, Luca
    Simonetti, Edoardo
    Merluzzi, Mara
    Bennati, Antonio
    Perriello, Vincenzo Maria
    Pucciarini, Alessandra
    Santi, Alessia
    Venanzi, Alessandra
    Pettirossi, Valentina
    Schiavoni, Gianluca
    Tasselli, Luisa
    Ascani, Stefano
    Volpetti, Stefano
    Falini, Brunangelo
    LEUKEMIA, 2021, 35 (11) : 3314 - 3318
  • [3] Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial
    Enrico Tiacci
    Luca De Carolis
    Edoardo Simonetti
    Mara Merluzzi
    Antonio Bennati
    Vincenzo Maria Perriello
    Alessandra Pucciarini
    Alessia Santi
    Alessandra Venanzi
    Valentina Pettirossi
    Gianluca Schiavoni
    Luisa Tasselli
    Stefano Ascani
    Stefano Volpetti
    Brunangelo Falini
    Leukemia, 2021, 35 : 3314 - 3318
  • [4] Efficacy and Safety of the BRAF Inhibitor Vemurafenib in Hairy Cell Leukemia Patients Refractory to or Relapsed after Purine Analogs: A Phase-2 Italian Clinical Trial
    Tiacci, Enrico
    De Carolis, Luca
    Zinzani, Pier Luigi
    Pulsoni, Alessandro
    Zaja, Francesco
    Cimminiello, Michele
    Ambrosetti, Achille
    Rossi, Davide
    Motta, Giovanna
    Varettoni, Marzia
    Fraticelli, Vincenzo
    Carella, Angelo Michele
    Anastasia, Antonella
    Leoni, Pietro
    Rambaldi, Alessandro
    Pileri, Stefano Aldo
    Foa, Robin
    Falini, Brunangelo
    BLOOD, 2014, 124 (21)
  • [5] Real-Life Efficacy and Safety of Vemurafenib Plus Rituximab (V plus R) in Relapsed or Refractory Hairy Cell Leukemia: A Multi-Center Retrospective Study (HCL-PG03R)
    Tiacci, Enrico
    De Carolis, Luca
    Capponi, Monia
    Bernardelli, Andrea
    Visentin, Andrea
    D'Elia, Gianna Maria
    Ferrero, Simone
    Cimminiello, Michele
    Romeo, Azzurra Anna
    Pocali, Barbara
    Falcinelli, Flavio
    Sanna, Alessandro
    Frustaci, Annamaria
    Maschio, Nilla
    Stelitano, Caterina
    Olivieri, Jacopo
    Visco, Carlo
    Pulsoni, Alessandro
    Foa, Robin
    Trentin, Livio
    Falini, Brunangelo
    BLOOD, 2023, 142
  • [6] Moxetumomab pasudotox in heavily pretreated patients (pts) with relapsed/refractory Hairy Cell Leukemia (r/r HCL): Long-term follow-up from the pivotal phase 3 trial
    le Coutre, P.
    Dietrich, S.
    Rummel, M.
    Daerden, C.
    Zinzani, P. L.
    Delgado, J.
    Robak, T.
    Gjertsen, B.
    Troussard, X.
    Roboz, G.
    Karlin, L.
    Gladstone, D.
    Wilson, W.
    Pastan, I
    Giles, F.
    Kreitman, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 69 - 69
  • [7] VEMURAFENIB IS SAFE AND HIGHLY ACTIVE IN HAIRY CELL LEUKEMIA PATIENTS REFRACTORY TO OR RELAPSED AFTER PURINE ANALOGS: A PHASE-2 ITALIAN CLINICAL TRIAL
    Tiacci, E.
    De Carolis, L.
    Zinzani, P. L.
    Pulsoni, A.
    Mazzucco, M.
    Cimminiello, M.
    Ambrosetti, A.
    Rossi, D.
    Motta, G.
    Varettoni, M.
    Fraticelli, V.
    Carella, A. M.
    Anastasia, A.
    Leoni, P.
    Rambaldi, A.
    Pileri, S. A.
    Foa, R.
    Falini, B.
    HAEMATOLOGICA, 2014, 99 : 245 - 246
  • [8] Efficacy and safety of moxetumomab pasudotox (moxe) in adult patients (pts) with relapsed/refractory hairy cell leukemia (HCL) in relation to drug exposure, baseline disease burden, and immunogenicity.
    Kuruvilla, Denison
    Chia, Yen Lin
    Santiago, Linda
    Balic, Kemal
    Yao, Nai-Shun
    Kreitman, Robert J.
    Pastan, Ira
    Li, Xia
    Liang, Meina
    Tseng, Chih-Ming
    Faggioni, Raffaella
    Roskos, Lorin
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] Tuspetinib Myeloid Kinase Inhibitor Safety and Efficacy As Monotherapy and Combined with Venetoclax in Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)
    Daver, Naval
    Lee, Kyoo Hyung
    Choi, Yunsuk
    Jonas, Brian A.
    Arellano, Martha
    Koller, Paul B.
    Jung, Chul W.
    Sohn, Sang Kyun
    Fathi, Amir T.
    Lee, Jeong-Ok
    Yoon, Sung-Soo
    Watts, Justin M.
    Vachhani, Pankit
    Shin, Ho-Jin
    Hu, Jia
    Sinha, Ranjeet
    Khan, Nawazish
    Rice, William G.
    Bejar, Rafael
    BLOOD, 2023, 142
  • [10] Primary Analysis of the Phase 2 ELARA Trial: Tisagenlecleucel Efficacy and Safety in Adult Patients with Relapsed/Refractory Follicular Lymphoma (r/r FL)
    Schuster, Stephen J.
    Dickinson, Michael
    Dreyling, Martin
    Martinez-Lopez, Joaquin
    Kolstad, Arne
    Butler, Jason
    Ghosh, Monalisa
    Popplewell, Leslie
    Chavez, Julio C.
    Bachy, Emmanuel
    Kato, Koji
    Harigae, Hideo
    Kersten, Marie Jose
    Andreadis, Charalambos
    Riedell, Peter
    Zia, Aiesha
    Morisse, Mony Chenda
    Fowler, Nathan Hale
    Thieblemont, Catherine
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S403 - S404
12345